Skip to Content
Merck
All Photos(1)

Documents

G004366

HPLC Analysis of Verapamil and Metabolites in Rat Plasma on Ascentis® Express C18 after Phospholipid Removal using HybridSPE®-Phospholipid

application for SPE, application for LC-MS

Sign Into View Organizational & Contract Pricing


About This Item

technique(s)

LC/MS: suitable
solid phase extraction (SPE): suitable

test parameters

SPE well plate: HybridSPE-Precipitation 96-well Plate, 50 mg/well (575656-U)
sample preparation: SPE (Solid Phase Extraction)
column: Ascentis Express C18, 5 cm x 2.1 mm I.D., 2.7 μm particles (53822-U)
sample/matrix: Rat plasma spiked with verapamil and metabolites at 10 ng/mL
mobile phase: [A] water; [B] acetonitrile, pH 2.55 adjust with formic acid (30:70, A:B)
flow rate: 0.6 mL/min
column temp.: 35 °C
detector: TOF/MS
injection: 1 μL
sample addition: 100 μL spiked rat plasma followed by 300 μL 1% formic acid in acetonitrile
elution: apply vacuum

suitability

application for LC-MS
application for SPE

application(s)

clinical

Legal Information

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany
HybridSPE is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service